PH12022551456A1 - Methods of treating iga nephropathy with atrasentan - Google Patents
Methods of treating iga nephropathy with atrasentanInfo
- Publication number
- PH12022551456A1 PH12022551456A1 PH1/2022/551456A PH12022551456A PH12022551456A1 PH 12022551456 A1 PH12022551456 A1 PH 12022551456A1 PH 12022551456 A PH12022551456 A PH 12022551456A PH 12022551456 A1 PH12022551456 A1 PH 12022551456A1
- Authority
- PH
- Philippines
- Prior art keywords
- decreasing
- nephropathy
- subject
- atrasentan
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962949115P | 2019-12-17 | 2019-12-17 | |
| US202063005003P | 2020-04-03 | 2020-04-03 | |
| US202063072699P | 2020-08-31 | 2020-08-31 | |
| US202063084739P | 2020-09-29 | 2020-09-29 | |
| US202063125205P | 2020-12-14 | 2020-12-14 | |
| PCT/US2020/065311 WO2021126977A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022551456A1 true PH12022551456A1 (en) | 2023-10-23 |
Family
ID=76478538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/551456A PH12022551456A1 (en) | 2019-12-17 | 2020-12-16 | Methods of treating iga nephropathy with atrasentan |
Country Status (21)
| Country | Link |
|---|---|
| US (11) | US20210353593A1 (https=) |
| EP (2) | EP4076652B1 (https=) |
| JP (2) | JP7624995B2 (https=) |
| KR (1) | KR20230015874A (https=) |
| CN (3) | CN116173014A (https=) |
| AU (1) | AU2020404984A1 (https=) |
| BR (1) | BR112022012075A2 (https=) |
| CA (1) | CA3161516A1 (https=) |
| DK (1) | DK4076652T3 (https=) |
| FI (1) | FI4076652T3 (https=) |
| HR (1) | HRP20260121T1 (https=) |
| IL (1) | IL293921A (https=) |
| LT (1) | LT4076652T (https=) |
| MX (1) | MX2022007471A (https=) |
| PH (1) | PH12022551456A1 (https=) |
| PL (1) | PL4076652T3 (https=) |
| PT (1) | PT4076652T (https=) |
| RS (1) | RS67746B1 (https=) |
| SI (1) | SI4076652T1 (https=) |
| TW (1) | TWI875895B (https=) |
| WO (1) | WO2021126977A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3161516A1 (en) | 2019-12-17 | 2021-06-24 | Philip Thomas FROHLICH | Methods of treating iga nephropathy with atrasentan |
| CN114910647A (zh) * | 2022-05-07 | 2022-08-16 | 浙江大学 | 细丝蛋白-A-IgG抗体在制备检测血管内皮损伤试剂盒中的应用 |
| WO2023220930A1 (en) * | 2022-05-17 | 2023-11-23 | Increvet, Inc. | Veterinary pharmaceutical formulations cross-references to related applications |
| CN119325377A (zh) * | 2022-05-19 | 2025-01-17 | 奇努克治疗公司 | 用阿曲生坦治疗局灶节段性肾小球硬化的方法 |
| WO2024073672A1 (en) | 2022-09-30 | 2024-04-04 | Travere Therapeutics, Inc. | Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders |
| WO2024076177A1 (ko) * | 2022-10-05 | 2024-04-11 | 주식회사 대웅제약 | 이나보글리플로진을 포함하는 신장애 및/또는 당뇨병 예방 또는 치료용 약학 조성물 |
| AU2023366516A1 (en) * | 2022-10-28 | 2025-05-15 | Aduro Biotech Holdings, Europe B.V. | Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody |
| JP2025536433A (ja) | 2022-11-07 | 2025-11-05 | サンレノ セラピューティクス （シャンハイ） リミテッド | ＩｇＡ腎症を治療するためのエンドセリン受容体アンタゴニストとグルココルチコイドとの組み合わせ |
| WO2025261457A1 (zh) * | 2024-06-21 | 2025-12-26 | 深圳信立泰药业股份有限公司 | 内皮素a(eta)受体拮抗剂联用sglt-2抑制剂的医药用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5236940A (en) | 1988-12-15 | 1993-08-17 | Rhone-Poulenc Sante | Pharmaceutical compositions, 2-benzothiazolamine derivatives, and their preparation |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| US7365093B2 (en) | 1994-08-19 | 2008-04-29 | Abbott Laboratories | Endothelin antagonists |
| US7208517B1 (en) | 1994-08-19 | 2007-04-24 | Abbott Labortories | Endothelin antagonists |
| US6946481B1 (en) | 1994-08-19 | 2005-09-20 | Abbott Laboratories | Endothelin antagonists |
| US20020062121A1 (en) | 1995-05-16 | 2002-05-23 | Karl Tryggvason | Perfusion apparatus and methods for pharmaceutical delivery |
| PT885215E (pt) | 1996-02-13 | 2006-08-31 | Abbott Lab | Novos derivados de pirrolidina substituidos com benzo-1,3-dioxolilo e benzofuranilo como antagonistas de endotelina |
| US20040191774A1 (en) | 2001-09-11 | 2004-09-30 | Moskowitz David W | Endothelin-1 promoter polymorphism |
| KR100964908B1 (ko) | 2002-03-22 | 2010-06-23 | 깃세이 야쿠힌 고교 가부시키가이샤 | 신장질환의 예방 또는 치료제 |
| AU2003226356A1 (en) | 2002-04-12 | 2003-10-27 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| US20030229906A1 (en) | 2002-04-15 | 2003-12-11 | Gelman Irwin H. | Methods and compositions for the treatment of disorders of HIV infection |
| US9388427B2 (en) | 2002-12-02 | 2016-07-12 | Biovec, Llc | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| US7410483B2 (en) | 2003-05-23 | 2008-08-12 | Novare Surgical Systems, Inc. | Hand-actuated device for remote manipulation of a grasping tool |
| US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| EP1802610A1 (en) | 2004-09-17 | 2007-07-04 | Abbott Laboratories | Crystalline form 2 of atrasentan hydrochloride |
| US9051301B2 (en) | 2004-09-17 | 2015-06-09 | Abbvie Inc. | Crystalline form of a drug |
| US20060135596A1 (en) | 2004-09-17 | 2006-06-22 | Zhang Geoff G | Amorphous form of a drug |
| WO2006034094A1 (en) | 2004-09-17 | 2006-03-30 | Abbott Laboratories | Crystalline form 1 of atrasentan hxdrochloride |
| EP2012751A4 (en) | 2006-03-21 | 2010-11-24 | Morehouse School Of Medicine | NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION |
| BRPI0709411A2 (pt) * | 2006-03-27 | 2011-07-12 | Genentech Inc | método para tratamento de uma doença renal |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| CA2667364A1 (en) | 2007-01-16 | 2008-07-24 | Musc Foundation For Research Development | Compositions and methods for diagnosing, treating, and preventing prostate conditions |
| CA2695259C (en) | 2007-07-31 | 2016-05-24 | Gilead Colorado, Inc. | Metabolites and derivatives of ambrisentan |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| US20120083421A1 (en) | 2008-10-16 | 2012-04-05 | The Trustees Of Columbia University In The City Of New York | Use of urinary ngal to diagnose and monitor hiv-associated nephropathy (hivan) |
| WO2010114801A1 (en) | 2009-03-31 | 2010-10-07 | Ligand Pharmaceuticals Inc. | Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy |
| EP2509594A1 (en) | 2009-12-09 | 2012-10-17 | INSERM - Institut National de la Santé et de la Recherche Médicale | Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis |
| US9255931B2 (en) * | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| CN103025670B (zh) | 2010-07-28 | 2016-08-10 | 日本电气硝子株式会社 | 荧光体封入用毛细管的制造方法、荧光体封入用毛细管、波长变换部件和波长变换部件的制造方法 |
| CN105324395A (zh) * | 2013-03-08 | 2016-02-10 | 艾伯维公司 | 治疗急性肾损伤的方法 |
| KR20160003128A (ko) | 2013-04-30 | 2016-01-08 | 애브비 인코포레이티드 | 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법 |
| US9364458B2 (en) * | 2013-07-08 | 2016-06-14 | Abbvie Inc. | Stabilized pharmaceutical dosage forms comprising atrasentan |
| NL2011406C2 (en) | 2013-09-06 | 2015-03-10 | Bionovion Holding B V | Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides. |
| US8962675B1 (en) | 2013-09-12 | 2015-02-24 | Abbvie Inc. | Atrasentan mandelate salts |
| AU2015342929A1 (en) * | 2014-11-07 | 2017-05-25 | Abbvie Inc. | Methods of treating CKD using predictors of fluid retention |
| NL2014108B1 (en) | 2015-01-09 | 2016-09-30 | Aduro Biotech Holdings Europe B V | Altered april binding antibodies. |
| US20170014386A1 (en) | 2015-07-16 | 2017-01-19 | Abbvie, Inc. | Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children |
| IL300122A (en) * | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| KR102528260B1 (ko) | 2016-01-05 | 2023-05-04 | 유니버시티 오브 레스터 | 필요로 하는 대상체에서 섬유증의 억제 방법 |
| CN117017985A (zh) * | 2016-10-13 | 2023-11-10 | 特拉维尔治疗公司 | 用于治疗肾脏疾病或病症的联苯磺酰胺化合物 |
| RU2765737C2 (ru) | 2016-11-23 | 2022-02-02 | Хемоцентрикс, Инк. | Способ лечения фокально-сегментарного гломерулосклероза |
| RU2020113612A (ru) | 2017-10-11 | 2021-11-12 | Хемоцентрикс, Инк. | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 |
| CN111405899B (zh) | 2017-11-30 | 2025-05-16 | 爱杜西亚药品有限公司 | 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合 |
| US20220304979A1 (en) | 2019-12-17 | 2022-09-29 | Chinook Therapeutics, Inc. | Methods of reducing disease flares |
| CA3161516A1 (en) * | 2019-12-17 | 2021-06-24 | Philip Thomas FROHLICH | Methods of treating iga nephropathy with atrasentan |
| IL297208A (en) | 2020-04-10 | 2022-12-01 | Chinook Therapeutics Inc | Treatment methods for diabetic kidney disease |
| US20220243994A1 (en) | 2021-02-04 | 2022-08-04 | Northrop Grumman Systems Corporation | Metal woodpile capillary wick |
-
2020
- 2020-12-16 CA CA3161516A patent/CA3161516A1/en active Pending
- 2020-12-16 CN CN202310043259.3A patent/CN116173014A/zh active Pending
- 2020-12-16 FI FIEP20903533.6T patent/FI4076652T3/fi active
- 2020-12-16 AU AU2020404984A patent/AU2020404984A1/en active Pending
- 2020-12-16 CN CN202310043260.6A patent/CN116327758A/zh active Pending
- 2020-12-16 MX MX2022007471A patent/MX2022007471A/es unknown
- 2020-12-16 SI SI202030727T patent/SI4076652T1/sl unknown
- 2020-12-16 KR KR1020227024511A patent/KR20230015874A/ko active Pending
- 2020-12-16 EP EP20903533.6A patent/EP4076652B1/en active Active
- 2020-12-16 EP EP25219043.4A patent/EP4710928A3/en active Pending
- 2020-12-16 PL PL20903533.6T patent/PL4076652T3/pl unknown
- 2020-12-16 RS RS20260142A patent/RS67746B1/sr unknown
- 2020-12-16 PT PT209035336T patent/PT4076652T/pt unknown
- 2020-12-16 HR HRP20260121TT patent/HRP20260121T1/hr unknown
- 2020-12-16 BR BR112022012075A patent/BR112022012075A2/pt unknown
- 2020-12-16 CN CN202080007568.XA patent/CN113272013A/zh active Pending
- 2020-12-16 WO PCT/US2020/065311 patent/WO2021126977A1/en not_active Ceased
- 2020-12-16 IL IL293921A patent/IL293921A/en unknown
- 2020-12-16 LT LTEPPCT/US2020/065311T patent/LT4076652T/lt unknown
- 2020-12-16 JP JP2022537007A patent/JP7624995B2/ja active Active
- 2020-12-16 DK DK20903533.6T patent/DK4076652T3/da active
- 2020-12-16 PH PH1/2022/551456A patent/PH12022551456A1/en unknown
- 2020-12-16 TW TW109144568A patent/TWI875895B/zh active
-
2021
- 2021-06-30 US US17/363,604 patent/US20210353593A1/en not_active Abandoned
-
2022
- 2022-05-27 US US17/826,832 patent/US20220288026A1/en not_active Abandoned
- 2022-05-27 US US17/826,753 patent/US20220304978A1/en not_active Abandoned
- 2022-05-27 US US17/826,843 patent/US11491137B2/en active Active
- 2022-08-16 US US17/888,766 patent/US12582631B2/en active Active
-
2023
- 2023-07-18 US US18/223,355 patent/US12121509B2/en active Active
- 2023-07-18 US US18/223,290 patent/US20230355579A1/en not_active Abandoned
- 2023-07-18 US US18/223,340 patent/US11998526B2/en active Active
- 2023-11-29 US US18/523,609 patent/US12521369B2/en active Active
-
2024
- 2024-09-13 US US18/884,802 patent/US20250281454A1/en active Pending
- 2024-12-12 JP JP2024218275A patent/JP7821870B2/ja active Active
- 2024-12-20 US US18/990,351 patent/US12370174B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551456A1 (en) | Methods of treating iga nephropathy with atrasentan | |
| PH12022552702A1 (en) | Methods of treating diabetic kidney disease | |
| ZA202203775B (en) | Substituted cyanopyrrolidines with activity as usp30 inhibitors | |
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| CL2020001066A1 (es) | Compuestos y métodos para la reducción de la expresión de snca. | |
| EA201892657A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| MX2019014410A (es) | Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| JOP20190112A1 (ar) | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي | |
| WO2022218941A3 (en) | Compositions and methods for inhibiting ketohexokinase (khk) | |
| WO2018052891A3 (en) | MODULATION OF PCSK9 AND LDLR BY INHIBITION OF DRP1 | |
| AU2017276588A1 (en) | Physiologically balanced injectable formulations of fosnetupitant | |
| EP4342985A3 (en) | Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components | |
| EP4438618A3 (en) | Cyclosporine compositions and methods of use | |
| EP4056638A4 (en) | COMPOSITION OF CELLULOSE, TABLET AND ORODISPERSIBLE TABLET | |
| TW202615002A (zh) | 用阿曲生坦（ＡＴＲＡＳＥＮＴＡＮ）治療ＩｇＡ腎病的方法 | |
| EP4218753A3 (en) | Compounds for the reducing lipotoxic damage | |
| JOP20220292A1 (ar) | صياغات صيدلانية من أسيتات أبيراتيرون ونيراباريب | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| MX2024013985A (es) | Metodos de tratamiento de la glomeruloesclerosis focal y segmentaria con atrasentan | |
| Valentin et al. | Pregabalin as adjunctive therapy for partial epilepsy: an audit study in 96 patients from the South East of England | |
| WO2023019095A3 (en) | Momelotinib combination therapy | |
| ZA202201070B (en) | Focal treatment of prostate cancer | |
| PH12019501260A1 (en) | A fast disintegrating pharmaceutical composition |